DNA gyrase: structure and function RJ Reece, A Maxwell Critical reviews in biochemistry and molecular biology 26 (3-4), 335-375, 1991 | 878 | 1991 |
Crystal structure of an N-terminal fragment of the DNA gyrase B protein DB Wigley, GJ Davies, EJ Dodson, A Maxwell, G Dodson Nature 351 (6328), 624-629, 1991 | 670 | 1991 |
Exploiting bacterial DNA gyrase as a drug target: current state and perspectives F Collin, S Karkare, A Maxwell Applied microbiology and biotechnology 92, 479-497, 2011 | 605 | 2011 |
Crystal structure of the breakage–reunion domain of DNA gyrase JHM Cabral, AP Jackson, CV Smith, N Shikotra, A Maxwell, ... Nature 388 (6645), 903-906, 1997 | 595 | 1997 |
DNA topology AD Bates, A Maxwell Oxford University Press, USA, 2005 | 579 | 2005 |
DNA gyrase as a drug target A Maxwell Trends in microbiology 5 (3), 102-109, 1997 | 456 | 1997 |
The 43-kilodalton N-terminal fragment of the DNA gyrase B protein hydrolyzes ATP and binds coumarin drugs JA Ali, AP Jackson, AJ Howells, A Maxwell Biochemistry 32 (10), 2717-2724, 1993 | 424 | 1993 |
The nature of inhibition of DNA gyrase by the coumarins and the cyclothialidines revealed by X‐ray crystallography. RJ Lewis, OM Singh, CV Smith, T Skarzynski, A Maxwell, AJ Wonacott, ... The EMBO journal 15 (6), 1412-1420, 1996 | 399 | 1996 |
A fluoroquinolone resistance protein from Mycobacterium tuberculosis that mimics DNA SS Hegde, MW Vetting, SL Roderick, LA Mitchenall, A Maxwell, HE Takiff, ... Science 308 (5727), 1480-1483, 2005 | 368 | 2005 |
A single point mutation in the DNA gyrase A protein greatly reduces binding of fluoroquinolones to the gyrase-DNA complex CJ Willmott, A Maxwell Antimicrobial agents and chemotherapy 37 (1), 126-127, 1993 | 362 | 1993 |
Mechanistic aspects of DNA topoisomerases A Maxwell, M Gellert Advances in protein chemistry 38, 69-107, 1986 | 343 | 1986 |
The interaction between coumarin drugs and DNA gyrase A Maxwell Molecular microbiology 9 (4), 681-686, 1993 | 339 | 1993 |
The ATP-binding site of type II topoisomerases as a target for antibacterial drugs A Maxwell, DM Lawson Current topics in medicinal chemistry 3 (3), 283-303, 2003 | 314 | 2003 |
Novobiocin: redesigning a DNA gyrase inhibitor for selective inhibition of hsp90 JA Burlison, L Neckers, AB Smith, A Maxwell, BSJ Blagg Journal of the American Chemical Society 128 (48), 15529-15536, 2006 | 282 | 2006 |
Arabidopsis SPO11‐2 functions with SPO11‐1 in meiotic recombination NJ Stacey, T Kuromori, Y Azumi, G Roberts, C Breuer, T Wada, A Maxwell, ... The Plant Journal 48 (2), 206-216, 2006 | 267 | 2006 |
Interaction between DNA Gyrase and Quinolones: Effects of Alanine Mutations at GyrA Subunit Residues Ser83and Asp87 FM Barnard, A Maxwell Antimicrobial agents and chemotherapy 45 (7), 1994-2000, 2001 | 254 | 2001 |
Quinolones: mechanism, lethality and their contributions to antibiotic resistance NG Bush, I Diez-Santos, LR Abbott, A Maxwell Molecules 25 (23), 5662, 2020 | 244 | 2020 |
DNA topology AD Bates, A Maxwell IRL Press at Oxford University Press, 1993 | 231 | 1993 |
The interaction of coumarin antibiotics with fragments of the DNA gyrase B protein NA Gormley, G Orphanides, A Meyer, PM Cullis, A Maxwell Biochemistry 35 (15), 5083-5092, 1996 | 221 | 1996 |
The molecular basis of quinolone action A MAXWELL Journal of Antimicrobial Chemotherapy 30 (4), 409-414, 1992 | 221 | 1992 |